The Neuroprotective Effect of Tyrosine Kinase Inhibitor Vorolanib in a Mouse Model of Retinal Detachment The DAVIO Trial: A Phase 1, Open-Label, Dose-Escalation Study of a Single Injection of EYP-1901 (Vorolanib in Durasert® Platform) Demonstrating Reduced Treatment Burden in Wet Age-Related Macular Degeneration 12-Month Results of a Tyrosine Kinase Inhibitor (Vorolanib) in a Bioerodible Durasert® Insert for Previously Treated Neovascular AMD: The DAVIO Trial 8-month Results of a Tyrosine Kinase Inhibitor (Vorolanib) in a Bio-erodible Durasert® Implant for Previously Treated Wet AMD: The DAVIO Trial Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
The Neuroprotective Effect of Tyrosine Kinase Inhibitor Vorolanib in a Mouse Model of Retinal Detachment
The DAVIO Trial: A Phase 1, Open-Label, Dose-Escalation Study of a Single Injection of EYP-1901 (Vorolanib in Durasert® Platform) Demonstrating Reduced Treatment Burden in Wet Age-Related Macular Degeneration
12-Month Results of a Tyrosine Kinase Inhibitor (Vorolanib) in a Bioerodible Durasert® Insert for Previously Treated Neovascular AMD: The DAVIO Trial
8-month Results of a Tyrosine Kinase Inhibitor (Vorolanib) in a Bio-erodible Durasert® Implant for Previously Treated Wet AMD: The DAVIO Trial
Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD